Clinical Trials

For a rare brain disease with no cure, a revolutionary trial design offers a faster path to treatment and renewed hope for thousands of patients and families.

X4 Pharmaceuticals secures a key European approval and overhauls its pivotal trial, signaling a major strategic shift backed by a newly extended cash runway.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.

With a Q3 FDA submission for its novel epilepsy drug azetukalner imminent, Xenon leverages a massive cash runway to expand into neuropsychiatry and pain.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.

Biotech firm MetaVia reports progress on its obesity drug DA-1726, with patients reaching high doses. Promising early data sets the stage for a pivotal Q4 readout.

Delcath Systems posts strong revenue and profits, but the real story is its massive investment in expanding its unique liver therapy to fight breast cancer and more.

A new clinical trial is testing a novel oncolytic virus, VCN-01, to break down pancreatic cancer's defenses, a key step toward a pivotal therapy.

Beyond the clinical data, ALX Oncology's latest update reveals a masterclass in strategic finance and leadership, positioning it for critical milestones.

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

vTv Therapeutics is nearing a critical milestone with its oral drug for Type 1 diabetes. Can it solve a deadly problem while navigating the financial tightrope?

A critical safety milestone for PepGen’s PGN-EDODM1 offers a glimmer of hope for myotonic dystrophy patients and highlights a novel strategy in a competitive field.

With the launch of its TED drug Lumvoa, Viridian Therapeutics steps into the commercial ring. But can early momentum and a deep pipeline justify the cost?

Priovant's Phase 3 trial for brepocitinib in cutaneous sarcoidosis isn't just about one disease. It's a key move in Roivant's playbook to build a rare disease powerhouse.

With nearly $800M in cash, Immunovant is all-in on a single drug, IMVT-1402. Can its ambitious six-front clinical strategy justify the burn and win the race?

With $60M in new funding and veteran pharma execs on board, Vedanta Biosciences is set for the pivotal last leg of its Phase 3 trial for VE303.

With a strong cash runway to 2028 and key data expected, Aclaris is advancing a multi-asset portfolio against complex immuno-inflammatory diseases.

With a pill aimed at both heart disease and blindness, BioAge Labs is betting its future on fighting aging itself. Is this the dawn of a new era in medicine?